세계 암 생물학적 제제 시장 규모는 2024년 941억 달러로 평가되며, 2030년까지 예측 기간 동안 7.17%의 CAGR을 기록하며 괄목할 만한 성장이 예상됩니다.
종양학 생물학적 제제 또는 바이오의약품으로도 알려진 암 생물학적 제제는 암 치료에 사용되는 약물의 한 종류입니다. 이러한 약물은 기존의 화학요법과는 달리 암의 성장, 진행, 전이에 관여하는 특정 분자나 경로를 표적으로 삼도록 설계되어 있습니다. 암 생물학적 제제는 살아있는 세포나 생물체에서 유래하는 경우가 많으며, 단클론항체, 사이토카인, 백신, 유전자 치료제 등 다양한 치료제가 포함됩니다. 이들 약제는 암세포의 증식과 분열을 촉진하는 신호를 억제합니다. 종양의 성장을 늦추고 종양에 영양을 공급하는 새로운 혈관의 형성을 막는 데 사용됩니다. 이러한 단클론항체는 두 개의 서로 다른 표적(종종 하나는 암세포에, 다른 하나는 면역세포에)에 동시에 결합할 수 있습니다. 이러한 항체는 면역체계와 암세포를 근접시켜 면역반응을 강화합니다. 암 생물학적 제제는 암세포와 정상세포 모두에 작용하는 기존 화학요법보다 더 표적화되고 특이적인 것으로 간주되는 경우가 많습니다. 이들은 환자의 면역 체계를 이용하여 암과 싸우는 광범위한 면역요법의 한 분야입니다. 예를 들어, 세계보건기구(WHO)의 예측에 따르면 2022년에는 약 2,000만 명이 새로 암에 걸리고 970만 명이 사망할 것으로 추정됩니다. 또한 암 진단 후 5년 후 생존해 있는 사람은 5,350만 명으로 예측되었으며, 5명 중 1명은 일생 동안 암을 경험하고, 남성 9명 중 1명, 여성 12명 중 1명은 암으로 사망할 것으로 예상했습니다. 폐암은 여전히 가장 높은 발병률을 보이며 전 세계 250만 명의 신규 환자, 즉 전체 신규 환자의 12.4%를 차지합니다. 폐암 다음으로 전립선암(150만 명, 7.3%), 위암(97만 명, 4.9%), 대장암(190만 명, 9.6%), 여성 유방암(230만 명, 11.6%)이 뒤를 잇습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 941억 달러 |
| 시장 규모 : 2030년 | 1,414억 3,000만 달러 |
| CAGR : 2025-2030년 | 7.17% |
| 급성장 부문 | 면역관문억제제 |
| 최대 시장 | 북미 |
생명공학 및 면역학 분야의 지속적인 연구개발과 혁신으로 보다 효과적이고 표적화된 암 생물학적 제제가 개발되고 있습니다. 새로운 발견과 기술 발전은 시장을 계속 발전시키고 있습니다. 맞춤형 의료의 추세는 특정 유전자 돌연변이 및 바이오마커를 표적으로 하는 생물학적 제제의 개발로 이어져 개별 암환자에게 맞춤화된 치료 옵션을 제공하고 있습니다. 면역관문억제제는 다양한 암종에서 괄목할 만한 성공을 거두었으며, 현재 진행 중인 연구에서 더 많은 암에 대한 적용이 검토되고 있어 시장 성장을 견인하고 있습니다. 잘 알려진 암 생물학적 제제에 대한 바이오시밀러의 개발 및 승인으로 경쟁이 치열해지고, 비용 절감 가능성이 시장 성장을 촉진하고 있습니다. 암 환자 지원 단체와 사회적 인식의 향상으로 혁신적인 치료법과 새로운 생물학적 제제 개발에 대한 수요가 증가하고 있습니다. 2024년 3월, 자이더스 라이프사이언스는 PARP 억제제인 올라파립(Olaparib)을 IBYRA라는 브랜드로 출시하여 인도의 모든 사람들이 고급 암 치료를 받을 수 있는 기회를 제공했습니다. 수 있도록 하였습니다. 폴리 ADP 리보스 중합효소(PARP)는 손상된 세포의 복구를 돕는 단백질로, PARP 억제제는 암세포에서 이 복구 과정을 억제하여 세포 사멸을 유도하는 작용을 합니다.
암 분야 투자 증가
인지도 향상과 환자 지원
높은 개발 비용
내성 및 반응 편차
단클론항체의 발전
Global Cancer Biologics Market was valued at USD 94.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.17% through 2030F. Cancer biologics, also known as oncology biologics or biopharmaceuticals, are a class of drugs used to treat cancer. These drugs are distinct from traditional chemotherapy and are designed to target specific molecules and pathways involved in the growth, progression, and spread of cancer. Cancer biologics are often derived from living cells or organisms and include a variety of therapeutic agents, such as monoclonal antibodies, cytokines, vaccines, and gene therapies. These drugs inhibit the signals that promote the growth and division of cancer cells. They can be used to slow tumor growth and prevent the formation of new blood vessels that feed the tumor. These monoclonal antibodies can simultaneously bind to two different targets, often one on a cancer cell and one on an immune cell. They bring the immune system into proximity with cancer cells, enhancing the immune response. Cancer biologics are often considered more targeted and specific than traditional chemotherapy, which can affect both cancer and healthy cells. They are part of the broader field of immunotherapy, which harnesses the patient's immune system to fight cancer. For instance, according to WHO predictions, approximately 20 million new cancer cases and 9.7 million deaths from the disease were estimated to occur in 2022. It was also projected that 53.5 million people would be living five years after being diagnosed with cancer. One in five individuals is expected to experience cancer during their lifetime, with roughly 1 in 9 men and 1 in 12 women dying from the condition. Lung cancer remains the most prevalent, comprising 2.5 million new cases worldwide, or 12.4% of all new cases. Following lung cancer, prostate cancer (1.5 million cases, 7.3%), stomach cancer (970,000 cases, 4.9%), colon cancer (1.9 million cases, 9.6%), and female breast cancer (2.3 million cases, 11.6%) are the next most common.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 94.10 Billion |
| Market Size 2030 | USD 141.43 Billion |
| CAGR 2025-2030 | 7.17% |
| Fastest Growing Segment | Immune Checkpoint Inhibitors |
| Largest Market | North America |
Ongoing research and innovation in the field of biotechnology and immunology have led to the development of more effective and targeted cancer biologics. New discoveries and technological advancements continue to drive the market forward. The trend toward personalized medicine has led to the development of biologics that target specific genetic mutations and biomarkers, providing tailored treatment options for individual cancer patients. Immune checkpoint inhibitors have shown remarkable success in various cancer types, and ongoing research explores their application in additional cancers, driving market growth. The development and approval of biosimilars for established cancer biologics have increased competition and the potential for cost savings, encouraging market growth. Cancer patient advocacy groups and increased public awareness have led to a greater demand for innovative treatments and the development of new biologics. Pharmaceutical companies are investing significantly in oncology research and development, leading to the discovery of new biologics and therapeutic targets. In March 2024, Zydus Lifescience made advanced cancer treatment more accessible to everyone in India by introducing olaparib, a PARP inhibitor, under the brand name IBYRA. Poly-ADP ribose polymerase, or PARP, is a protein that helps injured cells repair themselves. PARP inhibitors work by inhibiting this repair process in cancer cells, leading to cell death.
Key Market Drivers
Rising Investment in Oncology
Higher investment in oncology research and development (R&D) has led to the discovery and development of new cancer biologics. Pharmaceutical and biotechnology companies allocate substantial funds to conduct clinical trials, explore innovative treatment modalities, and discover novel targets for biologic therapies. Increased funding has led to the discovery of new cancer targets and the development of biologics specifically designed to target these markers. This has expanded the range of available treatment options and personalized medicine approaches. Investment supports a growing number of clinical trials, including large-scale, multi-phase trials for cancer biologics. These trials are essential for evaluating the safety and efficacy of new treatments, ultimately leading to regulatory approvals. Investment has fueled the growth of biotechnology startups dedicated to oncology. These startups often focus on niche areas and novel biologic therapies, contributing to the diversity of treatment options. For instance, in April 2023, TORL BioTherapeutics LLC announced a $158 million Series B fundraising round and its public launch as a biopharmaceutical company focused on developing innovative biologics for cancer treatment. The company's antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) pipeline was discovered in the lab of scientific co-founder Dennis Slamon, who is a professor of medicine at UCLA's David Geffen School of Medicine (DGSOM) and serves as the chief of the hematology/oncology division.
Greater investment encourages innovation in biologics development. Researchers and companies explore novel therapeutic approaches, such as bispecific antibodies, gene editing technologies, and advanced immunotherapies. Investment in oncology research and development extends beyond well-established markets, offering cancer patients worldwide access to cutting-edge biologic treatments. Investment enables the exploration of combination therapies, where biologics are used in conjunction with other treatment modalities, such as chemotherapy, targeted therapies, or radiation therapy. These combinations have shown promise in enhancing treatment efficacy. Funding supports advancements in biologics manufacturing processes, making production more efficient, cost-effective, and scalable. This ensures a stable supply of these treatments. Ongoing investment in oncology leads to the exploration of biologics in new clinical indications and cancer types, broadening the market and increasing treatment options for patients. Funds are allocated to navigate the complex regulatory pathways associated with biologics, increasing the number of approved treatments available for patients. Investment in biomarker research and diagnostic tools enables a more targeted and personalized approach to cancer treatment. Biologics are often used in conjunction with companion diagnostics to identify the most appropriate therapy for individual patients. This factor will pace up the demand of the Global Cancer Biologics Market.
Increasing Awareness and Patient Advocacy
Patient advocacy groups and awareness campaigns provide valuable information about cancer biologics, their benefits, and their availability. This empowers patients and their families to make informed decisions about their treatment options. Increased awareness often leads to earlier cancer detection, which can result in a better prognosis and more treatment options, including biologics. Patients and their advocates often push for access to the latest and most advanced cancer treatments, including biologics. This demand can lead to changes in healthcare policies and increased funding for these therapies. Patients who are aware of clinical trials involving cancer biologics may be more willing to participate in research, helping to advance the development of new treatments and expand treatment options. Patient advocacy and awareness efforts have contributed to the push for personalized medicine. Patients and advocacy groups advocate for treatments tailored to individual genetics and biomarkers, which is a central feature of many biologic therapies. Increased awareness can lead to greater patient access to specialized clinics and healthcare providers experienced in administering cancer biologics. For instance, with an annual incidence of 2.24 million cases and a mortality rate of 1.80 million, lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The two primary histological subtypes are non-small cell lung cancer (NSCLC), which accounts for 85% of cases, and small cell lung carcinoma (SCLC), making up 15% of all lung cancers.
Advocacy groups often raise funds for cancer research, including biologics development, through events, donations, and partnerships. This financial support helps drive further research and innovation. Increased awareness efforts aim to reduce the stigma surrounding cancer and cancer treatments, making it more acceptable for patients to explore various treatment options, including biologics. Advocacy groups often advocate for policy changes and regulatory reforms to improve the approval and accessibility of biologics, which can directly impact demand. Greater awareness can lead to higher enrollment in clinical trials, helping researchers gather valuable data on the efficacy and safety of biologic treatments, ultimately driving demand if positive results are achieved. By promoting early detection, personalized treatment, and advanced therapies like biologics, patient advocacy and awareness efforts contribute to improved patient outcomes, creating a growing demand for these treatments. Patient advocacy may focus on improving the quality of life for cancer patients. Biologics often have a more favorable side effect profile compared to traditional chemotherapy, making them a preferred choice for patients seeking a better quality of life during treatment. This factor will accelerate the demand of the Global Cancer Biologics Market.
Key Market Challenges
High Development Costs
Developing biologic therapies is a highly complex and resource-intensive process. It involves extensive preclinical research, clinical trials, and regulatory requirements, which all require substantial financial investments. Conducting clinical trials for cancer biologics, including Phase I, II, and III trials, is a costly endeavor. These trials involve patient recruitment, monitoring, data collection, and compliance with regulatory standards. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have stringent requirements for the approval of biologics. Meeting these standards necessitates significant investment in research and documentation. Biologics are challenging to manufacture due to their complexity. Establishing and maintaining the infrastructure for the large-scale production of biologics requires substantial capital. Maintaining the quality and consistency of biologics is vital to ensuring safety and efficacy. Stringent quality control and assurance processes contribute to development costs. Identifying appropriate biomarkers and targets for cancer biologics can be a resource-intensive process, requiring specialized research and expertise. Patient recruitment and ongoing monitoring in clinical trials involve substantial costs, including patient compensation, site expenses, and data management.
Resistance and Response Variability
Some cancer patients may exhibit innate or acquired resistance to certain biologics, meaning that the treatment may not be as effective as initially hoped. Tumors are often heterogeneous, with different regions of the tumor having distinct genetic profiles and responses to treatment. This heterogeneity can lead to resistance in certain tumor subpopulations. Patients can respond differently to biologic therapies due to factors such as genetics, overall health, and the presence of other medical conditions. This response variability can make it challenging to predict treatment outcomes accurately. The presence or absence of specific biomarkers, which are often used to select patients for certain biologics, can vary between individuals. This variability can impact the treatment's effectiveness. Cancer cells can adapt to treatment and develop resistance over time. This adaptability can lead to treatment failure and disease progression. Identifying the right patients for specific biologics based on predictive biomarkers is a complex process. Inadequate patient stratification can result in non-responders and treatment inefficiency. Developing and bringing new biologics to market is a costly and resource-intensive process. The potential for resistance and variability can increase the risks and costs associated with these endeavors.
Key Market Trends
Advancements in Monoclonal Antibodies
Monoclonal antibodies have been a cornerstone of cancer treatment for years, and ongoing advancements in this field are expanding their potential and impact. Bispecific monoclonal antibodies are designed to simultaneously target two different antigens or receptors, often present on cancer cells and immune cells. These bi-specific antibodies can enhance the immune system's ability to recognize and attack cancer cells, potentially leading to improved treatment outcomes. Immune checkpoint inhibitors are monoclonal antibodies that block proteins like PD-1 and PD-L1 to unleash the immune system's ability to attack cancer cells. Ongoing research is expanding the use of these inhibitors in various cancer types and as combination therapies. ADCs (Antibody-Drug Conjugates) are monoclonal antibodies that are chemically linked to cytotoxic drugs. These smart bombs selectively target cancer cells, delivering the drug payload directly to the tumor while sparing healthy tissue. Advancements in ADC technology have led to more effective and less toxic treatments. Researchers are continually identifying new cancer targets for monoclonal antibodies. This involves a deeper understanding of the molecular and genetic basis of cancer, leading to more precise targeting. Monoclonal antibodies are often used in combination with other immunotherapies or targeted therapies, leading to the development of innovative combination treatments to enhance treatment efficacy. Some monoclonal antibodies are being developed for subcutaneous administration, making treatment more convenient for patients compared to intravenous infusions. Advances in antibody engineering have led to the development of next-generation antibodies with enhanced properties, such as increased binding affinity, longer half-life, and improved tumor penetration. The identification of predictive biomarkers helps select patients who are most likely to respond to specific monoclonal antibody therapies, enabling a more personalized approach to treatment.
Segmental Insights
Application Insights
In 2024, the Global Cancer Biologics Market largest share was held by Acute Myeloid Leukemia segment and is predicted to continue expanding over the coming years. Cancer biologics play a crucial role in the treatment of breast cancer. These biologic therapies have been developed to target specific aspects of breast cancer biology, offering more targeted and effective treatment options. Human Epidermal Growth Factor Receptor 2 (HER2) is a protein that is overexpressed in some breast cancers. Biologics like trastuzumab (Herceptin) and pertuzumab (Perjeta) are monoclonal antibodies that specifically target HER2-positive breast cancers. They can block the growth signals of cancer cells and enhance the effectiveness of chemotherapy in these cases. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio), are used in combination with hormone therapy to treat hormone receptor-positive, HER2-negative metastatic breast cancer. These biologics inhibit specific proteins involved in cell division, slowing the progression of cancer. Some breast cancer patients benefit from immune checkpoint inhibitors, such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda). These biologics unleash the immune system to attack cancer cells by blocking the immune checkpoints that prevent immune cells from recognizing and destroying cancer. Bevacizumab (Avastin) is a biologic antibody used to inhibit angiogenesis, the formation of new blood vessels that supply tumors with nutrients. It can be combined with chemotherapy to treat certain types of advanced breast cancer.a
End-User Insights
In 2024, the Global Cancer Biologics Market largest share was held by Hospitals & Clinics segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals and clinics serve as primary points of access for cancer patients seeking diagnosis, treatment, and ongoing care. This results in a significant volume of cancer patients receiving biologics and other treatments within these healthcare settings. Hospitals and clinics offer comprehensive cancer care, including surgery, chemotherapy, radiation therapy, and biologics. They often have multidisciplinary teams of specialists who can coordinate and provide a range of treatments, including biologics, to address the complexity of cancer care. Healthcare professionals in hospitals and clinics have the expertise and experience required to administer biologics safely and effectively. They are equipped to handle the potential side effects and monitor patient responses. Many hospitals and academic medical centres actively participate in clinical trials and cancer research. This involvement allows them to offer patients access to cutting-edge biologics as part of clinical trial programs. Hospitals and clinics typically have advanced medical equipment and infrastructure necessary for the storage, preparation, and administration of biologics, which often require special handling and monitoring.
Regional Insights
The North America region dominated the Global Cancer Biologics Market in 2024. North America, particularly the United States and Canada, boasts highly advanced healthcare infrastructure and medical facilities. This allows for early diagnosis and effective treatment of cancer, including the use of biologics. The region is home to numerous leading biopharmaceutical companies, research institutions, and academic centers that are at the forefront of cancer biologics research and development. The United States has a well-established regulatory framework for the approval of biologics. The U.S. Food and Drug Administration (FDA) has a robust and transparent approval process that has encouraged the development and adoption of biologics. North America often serves as an early launch market for new biologics. This, in turn, leads to higher adoption rates and greater market share. Many global clinical trials for cancer biologics are conducted in North America, as it has a diverse and large patient population, streamlined regulatory processes, and skilled clinical trial infrastructure.
In this report, the Global Cancer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Cancer Biologics Market.
Global Cancer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: